EBMT Interview | The Latest Advances and Challenges in Bispecific Antibody Treatment for Lymphoma

EBMT Interview | The Latest Advances and Challenges in Bispecific Antibody Treatment for Lymphoma

Monoclonal antibody-based targeted therapy has significantly improved treatment options for cancer patients. In recent years, advancements in protein engineering have led to the development of bispecific antibodies (BsAbs), marking a paradigm shift in antibody construction usage. BsAbs, recognized for their higher therapeutic response, resistance barrier, and fewer adverse reactions, have caught significant attention in the academic world. The next wave of "bispecific or multispecific antibodies" is also on the horizon. At the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, Professor Maria Gomes Da Silva from the Portuguese Oncology Institute delivered an insightful report on the latest advances in BsAb treatments for lymphoma. "Oncology Frontier - Hematology Frontier" invited Professor Da Silva to share the latest developments and challenges in this field with our readers.
EBMT Spotlight Interview | Professor Li Chunfu: Improved TCRαβ-T Cell Depleted Hematopoietic Stem Cell Transplantation (TDH) for Treating Severe Thalassemia

EBMT Spotlight Interview | Professor Li Chunfu: Improved TCRαβ-T Cell Depleted Hematopoietic Stem Cell Transplantation (TDH) for Treating Severe Thalassemia

Hematopoietic stem cell transplantation is a common and effective treatment in the field of hematology. As techniques have matured, stem cell transplantation not only serves as a treatment for malignant blood diseases such as leukemia but also offers a new solution for curing thalassemia. The 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting took place in Glasgow, UK, from April 14th to 17th, 2024. The conference highlighted the latest advancements in stem cell transplantation and cellular therapies, pushing hematologic patients towards better clinical outcomes. At this meeting, Professor Li Chunfu from the Gaobo Medical (Hematology) Guangdong Research Center and Southern Chunfu (Children’s) Hematology Institute delivered an excellent oral presentation on the modified TCRαβ-T cell depleted hematopoietic stem cell transplantation (TDH) for treating severe thalassemia. "Oncology Frontier - Hematology Frontier" invited Professor Li to share his insights and experiences regarding transplantation treatments for thalassemia with our readers.
EBMT Interview Spotlight | Latest Advances and Challenges in CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL)

EBMT Interview Spotlight | Latest Advances and Challenges in CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia (ALL) is a malignant neoplastic disease that originates from B-cell or T-cell lymphocytes and proliferates abnormally in the bone marrow. In recent years, immunotherapy has made significant strides in the field of ALL, including breakthroughs in treatments such as Chimeric Antigen Receptor T-cell (CAR-T) therapy, bispecific antibodies, and antibody-drug conjugates (ADC). The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting took place in Glasgow, UK, from April 14 to 17, 2024. At the conference, Professor Peter Bader from the Department of Stem Cell Transplantation, Immunology, and Intensive Care Medicine at the University Hospital Frankfurt, Germany, delivered a special report on the current application of CAR-T therapy in ALL patients. Hematology Frontier invited Professor Bader to share the latest progress and challenges in CAR-T therapy in the field of ALL with a wide audience.
EBMT Interview Spotlight | Future Landscape of Multiple Myeloma Treatment: Cell Therapy vs. Transplantation

EBMT Interview Spotlight | Future Landscape of Multiple Myeloma Treatment: Cell Therapy vs. Transplantation

Multiple myeloma is a clonal plasma cell proliferative disorder that has seen significant therapeutic advancements over the past few decades due to deepening biological research. With the development of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, Chimeric Antigen Receptor T-cell (CAR-T) therapy, and other new drugs, the survival and prognosis for patients with multiple myeloma have undergone milestone changes. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was held in Glasgow, UK. At the conference, Professor Reuben Benjamin from King's College Hospital in London gave a special report on the clinical application and future prospects of hematopoietic stem cell transplantation and CAR-T cell therapy in multiple myeloma patients. Hematology News invited Professor Benjamin to share his insights with a broad audience.
Professor Jun Ma: Fruitful Updates to the 2024 CSCO Lymphoma Treatment Guidelines | 2024 CSCO Guidelines Conference

Professor Jun Ma: Fruitful Updates to the 2024 CSCO Lymphoma Treatment Guidelines | 2024 CSCO Guidelines Conference

Lymphoma has become the most prevalent malignant hematological tumor in China. Enhancing the standardized diagnosis and treatment of lymphoma is crucial for improving cure rates. The "Chinese Society of Clinical Oncology (CSCO) Lymphoma Treatment Guidelines" are updated annually and play a significant role in promoting standardized care for lymphoma. At the recent 2024 CSCO Guidelines Conference, the 2024 edition of the CSCO Lymphoma Treatment Guidelines was released as scheduled. To better understand the key updates in the 2024 edition, "Oncology Frontier - Hematology Frontier" invited Professor Jun Ma, Director of the Harbin Institute of Hematology Oncology, to discuss the current status of lymphoma diagnosis and treatment in China, and to share the significance and highlights of the new guidelines.
 Professor Tiejun Gong: Striving for Excellence, 2024 CSCO Guidelines on Malignant Hematology with a Focus on Leukemia | 2024 CSCO Guidelines Conference

 Professor Tiejun Gong: Striving for Excellence, 2024 CSCO Guidelines on Malignant Hematology with a Focus on Leukemia | 2024 CSCO Guidelines Conference

The 2024 China Clinical Oncology Society (CSCO) Guidelines Conference was held in Jinan on April 26-27, 2024. As always, the conference updated and released multiple CSCO cancer treatment guidelines. Professor Tiejun Gong, Deputy Director of the Harbin Institute of Hematologic Oncology, gave an insightful interpretation of the leukemia section in the "2024 CSCO Guidelines on Malignant Hematology." After the conference, "Oncology Frontier - Hematology Frontier" invited Professor Gong to introduce the characteristics and updates in leukemia treatment in the 2024 CSCO Malignant Hematology Guidelines, discuss current challenges in leukemia treatment, and express his views on potential improvements.
EBMT 2024 | Dr. Li Gao：The MRD status on day 7 and CD4 count at 1 month after CAR-T therapy are prognostic indicators in CAR-T treatments

EBMT 2024 | Dr. Li Gao：The MRD status on day 7 and CD4 count at 1 month after CAR-T therapy are prognostic indicators in CAR-T treatments

From April 14 to 17, 2024, the 50th Annual Congress of the European Society for Blood and Marrow Transplantation (EBMT) was held with great ceremony in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cell therapy, advancing patients with hematological diseases towards better clinical prognoses. At this congress, Dr. Li Gao from Soochow University Affiliated Children's Hospital reported on a study.
2024 CSCO Guideline Symposium: Professor Tiejun Gong: “Updates to the CSCO Guidelines for Malignant Hematologic Diseases” Drive Clinical Diagnosis

2024 CSCO Guideline Symposium: Professor Tiejun Gong: “Updates to the CSCO Guidelines for Malignant Hematologic Diseases” Drive Clinical Diagnosis

With the development of targeted therapy and immunotherapy, the treatment options for malignant hematologic diseases continue to expand. The "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Malignant Hematologic Diseases (2024)" has once again been updated. "Oncology Watch" specially interviewed one of the guideline's authors, Professor Tiejun Gong from the Harbin Institute of Hematology and Oncology, to provide in-depth explanations on the highlights of the guideline updates, their impact on clinical practice, and the implementation of the guidelines.
EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future

EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future

Induction therapies with high remission rates, combined with high-dose chemotherapy and autologous stem cell transplantation (ASCT), have significantly improved the prognosis for multiple myeloma (MM) patients. Despite this, patients still inevitably experience disease progression or relapse. One of the key goals in this research field is how to maintain remission in patients after induction therapy and ASCT. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting took place in Glasgow, UK, from April 14 to 17, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with hematological diseases and cancers. At this conference, Professor Jean-Luc Harousseau, Chairman of the French National Health Authority and Director of the René Gauducheau Cancer Center at the University of Nantes, delivered an insightful presentation on optimizing induction therapy strategies for multiple myeloma patients before ASCT. "Hematology Frontier" invited Professor Harousseau to share his insights on continuously optimizing pre-ASCT induction therapy for multiple myeloma patients.